Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Oligodendroglioma 1Neoplasm Metastasis 1Malignant Solid Tumor 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 37Radiotherapy 20Bevacizumab 14Carboplatin 10Magnetic Resonance Spectroscopy 9Carmustine 9antineoplaston AS 2-1 8antineoplaston A10 8Irinotecan 8Filgrastim 7Cyclophosphamide 6Cisplatin 6Etoposide 5sargramostim 4Vincristine 4Thiotepa 4Surgical Procedures, Operative 4Specimen Handling 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Everolimus 4Chemotherapy, Adjuvant 4trametinib 3aldesleukin 3Topotecan 3Thalidomide 3Tamoxifen 3Sunitinib 3Procarbazine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Astrocytoma × etirinotecan pegol × Clear all
NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡